Table 3.
Summary of information on the cancer patients carrying somatic mutations in the PRNP gene.
| Characteristics | All Cancer Patients | Subgroup 1 | Subgroup 2 | |
|---|---|---|---|---|
| Number of patients | 10,953 | 47 | 8 | |
| % compared to all cancer patients | - | 0.43% | 0.07% | |
| % compared to subgroup 1 | - | - | 17.02% | |
| Number of samples | 10,967 | 48 | 8 | |
| % compared to all cancer patients | 0.44% | 0.07% | ||
| % compared to subgroup 1 | - | - | 16.67% | |
| Diagnosis age (mean ± SD) | 59.1 ± 14.5 | 66 ± 12.8 | 66.3 ± 7.8 | |
| p-value compared to all cancer patients | 0.000742 | 0.093018 | ||
| p-value compared to subgroup 1 | - | - | 0.477389 | |
| Sex, N (%) | Male | 4866 (44.4%) | 18 (37.5%) | 3 (37.5%) |
| Female | 5315 (48.5%) | 27 (56.2%) | 4 (50.0%) | |
| NA | 772 (7.0%) | 3 (6.3%) | 1 (12.5%) | |
| Total | 10,953 | 48 | 8 | |
| p-value compared to all cancer patients | - | 0.30 | 0.79 | |
| p-value compared to subgroup 1 | - | - | 0.89 | |
| Mutation count | <100 | 6798 (67.3%) | 4 (8.3%) | 0 (0%) |
| 100 ≤ x < 200 | 1516 (15.0%) | 2 (4.2%) | 0 (0%) | |
| 200 ≤ x < 280 | 455 (4.5%) | 2 (4.2%) | 0 (0%) | |
| >280 | 1328 (13.2%) | 40 (83.3%) | 8 (100%) | |
| Total | 10,097 (100%) | 48 | 8 | |
| p-value compared to all cancer patients | - | <0.00001 | 2.3 × 10−11 | |
| p-value compared to subgroup 1 | - | - | 0.67 | |
| Cancer type, N (%) | Invasive breast carcinoma | 1084 (9.9%) | 0 (0%) | 0 (0%) |
| Non-small cell lung cancer | 1053 (9.6%) | 8 (16.7%) | 1 (12.5%) | |
| Colorectal adenocarcinoma | 594 (5.4%) | 2 (4.2%) | 1 (12.5%) | |
| Glioblastoma | 592 (5.4%) | 0 (0%) | 0 (0%) | |
| Endometrial carcinoma | 586 (5.3%) | 16 (33.3%) | 2 (25.0%) | |
| Ovarian epithelial tumor | 585 (5.3%) | 1 (2.1%) | 0 | |
| Head and neck squamous cell carcinoma | 523 (4.8%) | 1 (2.1%) | 1 (12.5%) | |
| Esophagogastric adenocarcinoma | 514 (4.7%) | 5 (10.4%) | 1 (12.5%) | |
| Diffuse glioma | 513 (4.7%) | 0 (0%) | 0 (0%) | |
| Renal clear cell carcinoma | 512 (4.7%) | 1 (2.1%) | 0 (0%) | |
| Well-differentiated thyroid | 500 (4.6%) | 0 (0%) | 0 (0%) | |
| Prostate adenocarcinoma | 494 (4.5%) | 0 (0%) | 0 (0%) | |
| Melanoma | 448 (4.1%) | 5 (10.4%) | 0 (0%) | |
| Bladder urothelial carcinoma | 411 (3.7%) | 2 (4.2%) | 0 (0%) | |
| Hepatocellular carcinoma | 369 (3.4%) | 0 (0%) | 0 (0%) | |
| Renal non-clear cell carcinoma | 348 (3.2%) | 3 (6.3%) | 1 (12.5%) | |
| Sarcoma | 255 (2.3%) | 1 (2.1%) | 0 (0%) | |
| Cervical squamous cell carcinoma | 251 (2.3%) | 1 (2.1%) | 1 (12.5%) | |
| Leukemia | 200 (1.8%) | 0 (0%) | 0 (0%) | |
| Pancreatic adenocarcinoma | 184 (1.7%) | 0 (0%) | 0 (0%) | |
| Pheochromocytoma | 147 (1.3%) | 0 (0%) | 0 (0%) | |
| Thymic epithelial tumor | 123 (1.1%) | 0 (0%) | 0 (0%) | |
| Esophageal squamous cell carcinoma | 95 (0.9%) | 1 (2.1%) | 0 (0%) | |
| Adrenocortical carcinoma | 92 (0.8%) | 0 (0%) | 0 (0%) | |
| Pleural mesothelioma | 87 (0.8%) | 0 (0%) | 0 (0%) | |
| Non-seminomatous germ cell tumor | 86 (0.8%) | 0 (0%) | 0 (0%) | |
| Ocular melanoma | 80 (0.7%) | 0 (0%) | 0 (0%) | |
| Seminoma | 63 (0.6%) | 0 (0%) | 0 (0%) | |
| Mature B-cell neoplasms | 48 (0.4%) | 0 (0%) | 0 (0%) | |
| Cervical adenocarcinoma | 46 (0.4%) | 0 (0%) | 0 (0%) | |
| Cholangiocarcinoma | 36 (0.3%) | 0 (0%) | 0 (0%) | |
| Miscellaneous neuroepithelial tumor | 31 (0.3%) | 0 (0%) | 0 (0%) | |
| Undifferentiated stomach adenocarcinoma | 13 (0.1%) | 1 (2.1%) | 0 (0%) | |
| Fibrolamellar carcinoma | 3 (<0.1%) | 0 (0%) | 0 (0%) | |
| Encapsulated glioma | 1 (<0.1%) | 0 (0%) | 0 (0%) | |
| Total | 10,967 | 48 | 8 | |
| p-value compared to all cancer patients | - | 6 × 10−12 | 0.96 | |
| p-value compared to subgroup 1 | - | - | NA |
Subgroup 1: carriers of PRNP somatic mutations. Subgroup 2: carriers of PRNP pathogenic somatic mutations of prion disease. NA: not available. Shaded boxes indicate pathogenic somatic mutations of prion disease. Bold text indicates statistical significance (p < 0.05).